Teva Pharmaceutical has launched AHZANTIVE (aflibercept), a biosimilar to Eylea, in Europe further strengthening the company’s growing biosimilars portfolio and expanding its presence in ophthalmology. The launch reflects Teva’s strategy to build a leading biosimilars business in areas of significant patient need and to broaden access to biologic medicines through strong partnerships, broad commercial capabilities, and reliable supply. 

The launch of AHZANTIVE pre-filled syringes began in May 2026 across several European markets, including France, Germany, Spain, and The Netherlands. The launch supports broader availability of biosimilar treatment options for patients living with serious retinal diseases and provides healthcare professionals with additional high-quality therapeutic choices. Teva expects to launch in additional markets later this year. The launch follows Teva’s semi-exclusive commercialisation agreement with Klinge Biopharma GmbH and Formycon AG in major parts of Europe and Israel. 

AHZANTIVE is a biosimilar to Eylea (aflibercept), with comparable efficacy, safety and immunogenicity to the reference product. It received European Commission (EC) approval in 2025 for the treatment of Neovascular Age-Related (wet) Macular Degeneration (nAMD) and other serious retinal diseases such as Diabetic Macular Edema (DME), visual impairment due to Myopic Choroidal Neovascularisation (CNV) and Macular Edema following Retinal Vein Occlusion (RVO). These chronic, vision-threatening conditions can create a significant burden for patients, caregivers and healthcare systems.

Yolanda Tibbe, Global Head of Biosimilars, Teva Pharma, said, “Biosimilars play a critical role in sustainable healthcare systems. With this launch, we are expanding our biosimilars portfolio with an important treatment option for people living with serious conditions that can threaten sight.”